| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 0 | 30 | 60 | 370 | 340 |
| Sales Growth | -100.00% | -50.00% | -83.78% | +8.82% | +1,033.34% |
| Net Income | 21,030 | -32,730 | -23,490 | -500 | -5,170 |
| Net Income Growth | +164.25% | -39.34% | -4,598.00% | +90.33% | -39.73% |
Oxis Intl Inc (OXIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oxis International, Inc. is a leader in the discovery, development and commercialization of therapeutic and diagnostic products to diagnose, treat and prevent diseases of oxidative stress. Oxidative stress occurs when the concentration of free radicals and reactive oxygen species, highly reactive molecules produced during oxidative processes, exceed the body's antioxidant defense mechanisms. The company has invested resources to build an early and substantial patent position on both its antioxidant therapeutic technologies and selected oxidative stress assays.